Known targets — ChEMBL curated mechanism
AURKABLKFGFR1FGFR2FGFR3FGFR4FGRFLT3FRKFYNHCKKDRLCKLYNPDGFRAPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Enmd-981693. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.69 |
| ▸ | CDK4 | P11802 | 1/20 | 0.69 |
| ▸ | CCND1 | P24385 | 1/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.69 |
| ▸ | CDK2 | P24941 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enmd-981693 SCHEMBL29350364 | 1.00 | CCNE2 (0.69) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL668748 | 0.94 | CCNE2 (0.57) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL8167814 | 0.93 | CCNE2 (0.69) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6440413 | 0.92 | CCNE2 (0.58) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7508119 | 0.92 | CCNE2 (0.56) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6427037 | 0.90 | CCNE2 (0.57) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6438493 | 0.90 | CCNE2 (0.55) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6425996 | 0.90 | CCNE2 (0.55) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6425702 | 0.89 | CCNE2 (0.54) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6424448 | 0.89 | CCNE2 (0.54) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242408-B1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | EP | claimed |
| US-RE36736-E | Substituted pyrroles | HOFFMAN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | claimed |
| US-20190185572-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3330292-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | Amgen, Inc (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9988457-B2 | Human C-FMS antigen binding proteins | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2188313-B1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170247459-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160340434-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| EP-1922337-B1 | TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES | AMGEN INC (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2822588-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2015-01-14 | — | — | EP | disclosed |
| US-20020061922-A1 | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability | ALBANO ANTONIO A (US) | 2002-05-23 | — | — | US | disclosed |
| WO-2002028855-A2 | AMORPHOUS FORM OF CELL CYCLE INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-11 | — | — | WO | disclosed |
| US-6326501-B1 | USING BASIC CATALYSTS; ENZYME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2001-12-04 | — | — | US | disclosed |
| WO-2001081305-A2 | METHYLATION OF INDOLE COMPOUNDS USING DIMETHY CARBONATE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001027106-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |
| US-RE36736-E | Substituted pyrroles | HOFFMAN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0328026-B1 | SUBSTITUTED PYRROLES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-28 | — | — | EP | disclosed |
| US-5057614-A | Antiinflammatory, immunology, bronchodilator agents, cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0328026-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061922-A1 | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability | CCNI, CDKN1A, CCNB1 | CCNE2 23/4885CDK4 39/4885CCND1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.